Home | Business News | Browse by Publication | T | Trial

Schering-Plough fined for off-label marketing, overcharging, kickbacks.

Article Excerpt
Pharmaceutical giant Schering-Plough Corp. recently announced it would pay $435 million as part of an agreement with the U.S. Attorney's Office for the District of Massachusetts and the U.S. Department of Justice (DOJ) to settle civil and criminal charges related to four of its prescription products. The investigation found that Schering improperly marketed its drugs for unapproved off-label uses, overcharged federal and state health care programs, and paid physicians kickbacks for prescribing certain drugs.

The charges involve the company's antihistamine Claritin; K-Dur, which treats stomach conditions; and the cancer drugs Temodar and Intron A. The agreement, announced August 29, is subject to court approval.

"The American people, as both taxpayers and consumers, expect our health care system to be free from fraud and corruption," said U.S. Attorney Michael Sullivan in a statement. "The pharmaceutical industry...

View this article FREE - Now for a Limited Time, try Goliath Business News
Free for 3 Days!